-
公开(公告)号：US20230416350A1
公开(公告)日：2023-12-28
申请号：US18344945
申请日：2023-06-30
Applicant: UCB BIOPHARMA SRL
Inventor： DAVID EDWARD ORMONDE KNIGHT , TERENCE SEWARD BAKER , DAVID JAMES MCMILLAN , ROBERT ANTHONY GRIFFIN , GEORGES MAIRET-COELLO , PATRICK DOWNEY , JEAN-PHILIPPE COURADE
CPC classification number: C07K16/18 , C07K14/4711 , A61P25/28 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2317/524 , C07K2317/526 , C07K2317/56 , C07K2317/70
Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
-
公开(公告)号：US20230374148A1
公开(公告)日：2023-11-23
申请号：US18248651
申请日：2021-10-14
Applicant: UCB BIOPHARMA SRL
Inventor： Stephen Edward RAPECKI , Ralph ADAMS , David Paul HUMPHREYS , Helen Margaret FINNEY , Rosemary Frances BITHELL
CPC classification number: C07K16/289 , C07K16/18 , A61P35/00 , A61P35/02 , C07K2317/31 , C07K2317/52 , C07K2317/24 , C07K2317/73 , C07K2317/72 , C07K2317/55 , C07K2317/92 , C07K2317/35
Abstract: The present invention provides binding molecule or molecules that are able to multimerise CD45 to induce cell death of a cell expressing CD45 without also inducing significant cytokine release. For example, the invention provides antibodies against CD45, wherein the antibodies comprise at least two different paratopes each specific for a different epitope of CD45. The antibodies may be used to cross-link CD45 on the surface of cells. The antibodies may be used in a variety of therapeutic ways including to deplete cells, for example prior to cell transplantation.
-
公开(公告)号：US20230331833A1
公开(公告)日：2023-10-19
申请号：US18344930
申请日：2023-06-30
Applicant: UCB BIOPHARMA SRL
Inventor： KERRY LOUISE TYSON , TERENCE SEWARD BAKER , GEORGES MAIRET-COELLO , PATRICK DOWNEY , JEAN-PHILIPPE COURADE , DAVID EDWARD ORMONDE KNIGHT
CPC classification number: C07K16/18 , C07K14/4711 , A61P25/28 , G01N33/6896 , A61K2039/505
Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
-
公开(公告)号：US20230303517A1
公开(公告)日：2023-09-28
申请号：US17786394
申请日：2020-12-22
Applicant: UCB Biopharma SRL
Inventor： Timothy John NORMAN , Douglas BYRNE , Julian Hugh ROWLEY , Giancarlo TRANI , Konstantinos RAMPALAKOS , Nathaniel Julius Thomas MONCK , Benedicte LALLEMAND , Gregory William HASLETT , Rickki Lee CONNELLY , Jag Paul HEER , James MADDEN , Oliver PHILPS , Selvaratnam SUGANTHAN , Zeshan YOUSUF , Richard John MEARS
IPC: C07D401/14 , C07D221/06 , C07D401/12 , C07D405/14 , C07D413/14 , C07D409/12 , C07D498/10 , C07D471/04 , C07D417/12 , C07D413/12 , C07D487/04 , C07D405/12
CPC classification number: C07D401/14 , C07D221/06 , C07D401/12 , C07D405/14 , C07D413/14 , C07D409/12 , C07D498/10 , C07D471/04 , C07D417/12 , C07D413/12 , C07D487/04 , C07D405/12
Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.
-
公开(公告)号：USD999906S1
公开(公告)日：2023-09-26
申请号：US29796504
申请日：2021-06-24
Applicant: UCB Biopharma SRL
Designer： Barry Alan Knight , David Francis Philbrick
Abstract: FIG. 1 is a top, front, left perspective view of a gripper for auto-injector needle shield, showing our new design;
FIG. 2 is a front elevation view thereof;
FIG. 3 is a rear elevation view thereof;
FIG. 4 is a left elevation view thereof;
FIG. 5 is a right elevation view thereof;
FIG. 6 is a top plan view thereof; and,
FIG. 7 is a bottom plan view thereof.-
Patent Agency Ranking
公开(公告)号：US11746145B2
公开(公告)日：2023-09-05
申请号：US17136440
申请日：2020-12-29
Applicant: UCB BIOPHARMA SRL
Inventor： Kerry Louise Tyson , Terence Seward Baker , Georges Mairet-Coello , Patrick Downey , Jean-Philippe Courade , David Edward Ormonde Knight
CPC classification number: C07K16/18 , A61P25/28 , C07K14/4711 , G01N33/6896 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/92 , G01N2333/4703 , G01N2800/28 , G01N2800/2821
Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
-
公开(公告)号：US20230192900A1
公开(公告)日：2023-06-22
申请号：US17929028
申请日：2020-02-13
Applicant: UCB BIOPHARMA SRL
Inventor： David Alan COOK , Helen Margaret FINNEY , Stephen Edward RAPECKI
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K2317/31 , C07K2317/24 , C07K2317/94 , C07K2317/565
Abstract: The present invention relates to multispecific antibodies against a novel targets' combination of HVEM and CD9, and their use in the treatment of cancer and infectious diseases.
-
公开(公告)号：US20230051300A1
公开(公告)日：2023-02-16
申请号：US17786295
申请日：2020-12-22
Applicant: UCB Biopharma SRL
Inventor： Timothy John NORMAN , Oliver PHILPS , Gregory William HASLETT , Jag Paul HEER , Giancarlo TRANI
IPC: C07D413/14 , C07D401/04 , C07D401/14 , C07D217/02 , C07D273/04 , C07D401/12
Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.
-
公开(公告)号：US11524997B2
公开(公告)日：2022-12-13
申请号：US16970391
申请日：2019-02-14
Applicant: UCB BIOPHARMA SRL
Inventor： Gareth Charles Glyndwr Davies , Scott John Roberts
IPC: A61K39/395 , C07K16/22 , A61P19/08
Abstract: The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.
-
100.发明申请公开(公告)号：US20220298528A1
公开(公告)日：2022-09-22
申请号：US17634112
申请日：2020-08-06
Applicant: UCB BIOPHARMA SRL , FUNDACION PARA LA INVESTIGACION MEDICA APLICADA , CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED
Abstract: The present disclosure relates to viral particles for use in treating synucleinopathies, particularly sporadic Parkinson Diseases by gene therapy. More specifically, the present invention relates to a viral particle for use in treating synucleinopathy by gene therapy in a subject in need thereof, said viral particle comprising a nucleic acid construct including a transgene encoding a glucocerebrosidase.
-
-
-
-
-
-
-
-
-
Search Results
209
records
(took 0.018 seconds)
